HAYWARD, Calif., Sept. 30 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that Robert L. Zerbe, M.D., has been elected to its Board of Directors.
Dr. Zerbe is the chief executive officer, director and co-founder of QuatRx Pharmaceuticals, Inc., located in Ann Arbor, MI. Dr. Zerbe has extensive experience in global clinical development and regulatory affairs. From 1982 to 2000, he held a variety of research and development positions, including managing director, Lilly Research Center U.K., senior vice president of worldwide clinical research and development at Parke Davis and senior vice president for Pfizer global research and development. He led the clinical development programs for key products including Lipitor(R) and Neurontin(R).
"Dr. Zerbe will bring to the board a unique blend of clinical and regulatory experience in metabolic disease coupled with operational experience in guiding development strategy in a small company," said Harold Van Wart, president and chief executive officer of Metabolex. "His expertise will be valuable in advancing the four drugs currently in our pipeline as well as other promising preclinical candidates."
Dr. Zerbe earned his medical degree at Indiana University in 1975, and completed his post-doctoral work in internal medicine, endocrinology, and neuroendocrinology at Indiana and the National Institutes of Health. He also serves on the boards of AP Pharma, Aastrom Biosciences, Anesiva Pharmaceuticals, and the Biotechnology Industry Organization Emerging Section Governing Body.
About Metabolex
Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, currently being studied in a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.
CONTACT: Donald Hill of Metabolex, Inc., +1-510-293-8800,
dhill@metabolex.com
Web site: http://www.metabolex.com/
